Iovance Biotherapeutics, Inc.
IOVA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $575,359 | $1,075,150 | $2,256,186 |
| - Cash | $158,134 | $132,469 | $171,668 | $115,694 |
| + Debt | $45,211 | $53,166 | $53,719 | $58,261 |
| Enterprise Value | – | $496,056 | $957,201 | $2,198,753 |
| Revenue | $67,455 | $59,952 | $49,324 | $73,694 |
| % Growth | 12.5% | 21.5% | -33.1% | – |
| Gross Profit | $66,047 | $3,288 | -$417 | $28,151 |
| % Margin | 97.9% | 5.5% | -0.8% | 38.2% |
| EBITDA | -$84,651 | -$101,836 | -$106,936 | -$74,889 |
| % Margin | -125.5% | -169.9% | -216.8% | -101.6% |
| Net Income | -$91,253 | -$111,658 | -$116,163 | -$78,559 |
| % Margin | -135.3% | -186.2% | -235.5% | -106.6% |
| EPS Diluted | -0.25 | -0.33 | -0.36 | -0.26 |
| % Growth | 24.2% | 8.3% | -38.5% | – |
| Operating Cash Flow | -$78,702 | -$67,447 | -$103,694 | -$73,296 |
| Capital Expenditures | -$10,844 | -$7,461 | -$6,211 | -$4,168 |
| Free Cash Flow | -$89,546 | -$74,908 | -$109,905 | -$77,464 |